Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort
International Journal of Tuberculosis and Lung Disease, Volume 16, No. 7, Year 2012
Notification
URL copied to clipboard!
Description
OBJECTIVE: To determine the frequency of and risk factors for major adverse drug reactions (MADRs) associated with anti-tuberculosis treatment at a tuberculosis (TB) referral hospital in the Republic of Korea. METHODS: Data from an ongoing natural history cohort study were analyzed for permanent regimen changes due to adverse drug reactions and confirmed by chart review. RESULTS: Among 655 subjects, there were 132 MADRs in 112 (17%) subjects. The most common MADRs were gastrointestinal (n = 53), musculoskeletal (n = 22), psychiatric (n = 10), visual (n = 9) and peripheral neuropathic (n = 8). MADRs were more frequent in subjects being treated with second-line regimens (16%) compared to first-line regimens (2.5%). Drugs frequently associated with MADRs were amikacin (3/10, 30%), linezolid (8/29, 28%), para-aminosalicylic acid (47/192, 24%), pyrazinamide (31/528, 5.8%), macrolides (2/44, 4.5%) and cycloserine (12/272, 4.4%). Fluoroquinolones accounted for a single MADR (1/377, 0.003%), despite widespread usage. In multivariate analysis, infection with multi- or extensively drug-resistant disease and previous history of anti-tuberculosis treatment were risk factors for MADR, with adjusted hazard ratios of respectively 2.2 (P = 0.02) and 1.6 (P = 0.04). CONCLUSION: MADRs are common during antit uberculosis chemotherapy in this population, occurring in more than one in six subjects. New and less toxic agents to treat drug-resistant TB are urgently needed. © 2012 The Union.
Authors & Co-Authors
Carroll, Matthew W.
United States, Bethesda
National Institutes of Health Nih
Lee, Myungsun
Unknown Affiliation
Cai, Ying
United States, Bethesda
National Institutes of Health Nih
Hallahan, Claire W.
United States, Bethesda
National Institutes of Health Nih
Shaw, Pamela A.
United States, Bethesda
National Institutes of Health Nih
Goldfeder, Lisa C.
United States, Bethesda
National Institutes of Health Nih
Kang, Hyeungseok
South Korea, Masan
National Masan Tuberculosis Hospital
Hwang, Soohee
United States, Bethesda
National Institutes of Health Nih
Jeon, Doosoo
United States, Bethesda
National Institutes of Health Nih
Via, L. E.
United States, Bethesda
National Institutes of Health Nih
Barry, Clifton Earl
United States, Bethesda
National Institutes of Health Nih
Statistics
Citations: 47
Authors: 11
Affiliations: 2
Identifiers
Doi:
10.5588/ijtld.11.0574
ISSN:
10273719
Research Areas
Cancer
Environmental
Health System And Policy
Infectious Diseases
Mental Health
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative